Table 3 COPD-treatment in percentage, stratified by recruitment source and GOLD-stage, results from unadjusted statistical comparison in the EconCOPD-study
From: Guideline adherence in hospital recruited and population based COPD patients
|  | GOLD 2 | GOLD 3–4 | ||
|---|---|---|---|---|
Population-based COPD cases (n = 76) Rank 1 | Hospital-recruited COPD patients (n = 118) Rank 2 | Population-based COPD cases (n = 14) Rank 3 | Hospital-recruited COPD patients (n = 127) Rank 4 | |
SAMA | 9.2 | 39.0 ** | 42.9 | 56.7 |
SABA | 23.7 | 45.8 ** | 42.9 | 55.9 |
LAMA | 1.3 | 15.3 ** | 14.3 | 28.4 |
LABA | 6.6 | 17.8 * | 14.3 | 13.4 |
ICS | 6.6 | 12.7 | 7.1 | 8.7 |
LABA+ICS in one device | 18.4 | 50.0 ** | 57.1 | 71.7 |
Methylxantines | 0.0 | 13.6 ** | 0.0 | 17.3 |
Oral beta2-agonist | 4.0 | 5.1 | 0.0 | 7.9 |
Prednisolone or methylprednisolone | 4.0 | 17.0 ** | 7.1 | 18.1 |
 -only short period | 2.6 | 5.1 | 7.1 | 8.7 |
Guideline adherent pharmacological treatment | 4.0 | 7.6 | 42.9 | 61.4 |
Self-reported doctors´ diagnosis of COPD, emphysema or chronic bronchitis | 27.6 | 80.5** | 71.4 | 92.1* |
Influenza vaccine preceding 12 months | 30.3 | 60.2** | 57.1 | 80.3 |
Rehabilitation | 5.3 | 11.0 | 7.1 | 22.1 |
Anti-smoking advice (if still smoking) *** | 82.9 | 93.6 | 80.0 | 100 |
Overall guideline adherence | 1.3 | 5.9 | 35.7 | 52.0 |
Overall guideline adherence AND rehabilitation, N (%) | 1 (1.3) | 1 (0.9) | 0 (0) | 17 (13.4) |